India’s First Indigenously Developed COVID-19 Vaccine Summarily Rejected by the West

The World Health Organization (WHO) rejected the emergency use authorization submission for Covaxin, the indigenously developed Indian COVID-19 vaccine developed by a partnership involving the apex research institute ICRM and the biotech venture Bharat Biotech. Actually, India’s first indigenously developed COVID-19 vaccine, the U.S. Food, and Drug Administration (FDA), already rejected a request for EUA back in the summer. In a blow to millions of Indian students and professionals that need to travel to other countries, their Covaxin vaccine won’t pass muster and must go get vaccinated again with a WHO-approved vaccine. Is Bharat Biotech and ICMR paying for an accelerated less than transparent effort?

In a recent statement, the All-India People’s Science Network (AIPSN) noted with “sorrow and grave concern” the WHO moves to reject the Covaxin EUL request. Rather WHO requested more technical details. Considered a “serious setback” for the Indian COVID-19 vaccine as well as for the vaccine development program in India, most importantly, AIPSN reports it’s “a blow to India’s plans to distribute vaccines to other countries.”

For example, many Indians travel worldwide for work o...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee